In the global registration trial for the CD19-targeting CAR T therapy tisagenlecleucel in B-ALL, 15 of the 16 relapses (94%) analyzed were CD19 negative (Maude et al. 2018). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.